Lynparzatm (olaparib) now available to NHS patients in England and Wales with BRCA-mutated ovarian cancer
AstraZeneca has announced that LynparzaTM (olaparib) is now available for NHS patients in England and Wales with platinum-sensitive relapsed (PSR) BRCA-mutated (BRCAm) high-grade serous ovarian… …read more